The transaction transforms Heron from a commercial-stage biotech with product revenue into a cash-rich entity with a significant equity stake in CorMedix and contingent royalty/earn-out streams. Monitor the proxy filing for stockholder vote timing and any competing acquisition proposals. Post-close, focus on CorMedix's commercial execution of the acquired products, particularly ZYNRELEF's sales trajectory toward the earn-out thresholds.
Drugs in focus
HRTX drug pipeline →ZYNRELEF
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and commercialized (FDA approved May 2021). Under the CorMedix asset purchase agreement, ZYNRELEF will transfer to CorMedix upon deal close, expected Q1 2027.
- Next catalyst
- None dated
What to watchZYNRELEF is now part of the asset sale to CorMedix (CRMD), expected to close in Q1 2027. For HRTX shareholders, the stock is transitioning into a stub: Heron will retain CRMD shares, net operating loss carryforwards (~$2.3B), and earn-out rights. The next event is the shareholder vote and regulatory clearance for the sale. For investors tracking ZYNRELEF specifically, watch CorMedix's commercial execution post-close and any label expansion efforts under new ownership.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $0.3706entry
- T+1 · 7d ago +0.94%α +1.31% · $0.3741
- T+5 · 21h ago −23.29%α −21.59% · $0.2843
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Heron Therapeutics (HRTX) entered into a definitive asset purchase agreement to sell its commercial-stage anti-nausea and post-operative pain product portfolio (CINVANTI, SUSTOL, ZYNRELEF) to CorMedix Inc. (CRMD) for $145M in cash plus 14,583,333 CRMD shares, along with tiered royalty payments on CINVANTI/SUSTOL net sales above a $25M threshold and earn-out payments on ZYNRELEF up to $55M. Concurrently, Heron exchanged its $35M convertible notes held by Rubric Capital Management for a portion of the CRMD stock consideration, effectively deleveraging its balance sheet. The transaction requires Heron stockholder approval and is expected to close within six months.
Key Financial Metrics
Key Facts
- Heron sells its commercial product portfolio (CINVANTI, SUSTOL, ZYNRELEF) to CorMedix for $145M cash plus 14,583,333 CRMD shares (Stock Consideration).
- Heron exchanges its $35M convertible notes held by Rubric Capital Management for a portion of the CRMD stock consideration, eliminating that debt.
- Heron is eligible for 5% royalty payments on CINVANTI/SUSTOL net sales above a $25M annual threshold for calendar years 2027-2029.
- Heron is eligible for earn-out payments on ZYNRELEF: $25M if 2028 net sales reach $65M, plus $30M if they reach $95M (max $55M).
- Heron stockholders must approve the transaction; closing conditions include antitrust clearance and Nasdaq listing of the CRMD shares.
- Heron will retain its corporate existence and certain excluded assets; the deal is structured as a taxable asset sale.
- Heron enters into a governance agreement with CorMedix, including board designation rights while ownership exceeds 10%.
- Heron agrees to a 5-year non-compete in the Field (aprepitant/granisetron injectables for nausea, bupivacaine/meloxicam for post-op pain).
- CorMedix has secured debt financing from BioPharma Credit PLC to fund the cash consideration.
Financial Impact
$145M base cash consideration plus 14,583,333 CRMD shares (value dependent on CRMD stock price at close), plus potential royalties and earn-outs up to $55M
Risk Factors
- Transaction requires Heron stockholder approval and antitrust clearance; failure would leave Heron with its current debt and product portfolio.
- Heron's post-close value is tied to CorMedix stock performance and the success of the acquired products, over which Heron has no operational control.
- Earn-out payments on ZYNRELEF are contingent on achieving aggressive net sales targets ($65M-$95M in 2028) and are not guaranteed.
- The non-compete restricts Heron from re-entering the nausea/pain injectable market for five years.
- CorMedix's ability to fund the cash consideration depends on its debt financing from BioPharma Credit PLC.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-452672 |
| Document: hrtx-ex10_3.htm | 0001193125-26-452672 |
| Document: hrtx-ex10_4.htm | 0001193125-26-452672 |
| Document: hrtx-ex10_2.htm | 0001193125-26-452672 |
Track record
15 reports on HRTX
4 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +58.33% at T+20 after the May 11, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 9, 20267d ago DEFA14A Neutral 6/10 Entry $0.3741 Now $0.2800 −25.15% settles Feb 8
- Nov 9, 20267d ago DEFA14A Neutral 6/10 Entry $0.3706 Now $0.2800 −24.45% settles Feb 5
- Nov 9, 20267d ago 8-K Neutral 6/10 Entry $0.3706 Now $0.2800 −24.45% settles Feb 5
- Nov 9, 20267d ago 8-K Neutral 6/10 Viewing Entry $0.3706 Now $0.2800 −24.45% settles Feb 5
- Nov 9, 20267d ago Press Release Mixed 7/10 Entry $0.3706 Now $0.2800 −24.45% settles Feb 5
- Aug 10, 202614w ago 8-K Bearish 7/10 No price data
- Aug 10, 202614w ago Press Release Bearish 7/10 Entry $0.3350 to $0.2847 Now $0.2800 +16.42% ▲ +15.01% +12.60% vs SPY
- Jun 25, 202620w ago 8-K Bearish 7/10 Entry $0.4300 to $0.2700 Now $0.2800 +34.88% ▲ +37.21% +43.31% vs SPY
- Jun 2, 202623w ago 8-K Bearish 7/10 Entry $0.4500 to $0.3321 Now $0.2800 +37.78% ▲ +26.20% +28.70% vs SPY
- May 11, 202627w ago 8-K Bearish 6/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers